All News
Is channelling bias a risk, because of treating clinicians 'protecting' pre-existing autoimmune dx pts: maybe?
Certainly in practice, these pts might get less combo immunoRx; this @mcgillu data would suggest so
Much more to understand across tumor streams
ABST0760 #ACR22 https://t.co/z1rhAJZ9gj
David Liew drdavidliew ( View Tweet)
What imaging modality is best in GCA?
Dutch study: n=42
?GCA got all three of USS, PET/CT, MRI
Overall performance basically the same between all three.
Important details in š§µ
but reasonable to say you can be happy with whatever youāve got!
ABST1617 #ACR22 #ACRBest @RheumNow https://t.co/HGt0vW9Z38
David Liew drdavidliew ( View Tweet)
To propose early intervention in pre-clinical PsA we need to first identify pts!
Eder et al. PRESTO Prediction of Psoriatic Arthritis Tool
Dvlped 600+ Pso
M stiff, PASI, nails, fatigue pain severity
Sens 61% Spe 77% for 5% proba PsA onset w/in 5yrs
Abs#1612 #ACR22 @Rheumnow https://t.co/QYOIKe3nui
Aurelie Najm AurelieRheumo ( View Tweet)
Tapryal et al. Diagnostic delay of >6 months contributes to poor PROs in PsA. @RheumNow #ACR22 Abstr#1507 https://t.co/dkaNhXUAeD https://t.co/6G7X7V1aRI
Richard Conway RichardPAConway ( View Tweet)
Data like this make us think even in the setting of a controlled clinical trial in #gout, non-white patients much less likely to achieve target serum urate!
Black pts 70% less likely to reach target compared to whites!
#ACR22 @RheumNow abst#1583 https://t.co/dYet7pk2l5
Bella Mehta bella_mehta ( View Tweet)
Jones et al. Non-smokers, normal BMI, and current drinkers! with AxSpA more likely to respond to TNFi. @RheumNow #ACR22 Abstr#1510 https://t.co/inCz2sAyj5 https://t.co/K27ptuLV7Y
Richard Conway RichardPAConway ( View Tweet)
Everyday heroes during #COVID19 Keynote @ACRheum Health care workers who were minorities disproportionately died in the early days of the pandemic. Canāt be all SES as risk but maybe āstatusā as first line workers. Remember them #ACRBest #ACR22 @RheumNow @AbrahamVerghese šš» https://t.co/AjkV5wDVEu
Janet Pope Janetbirdope ( View Tweet)
Only 4 minutes to discuss adherence in #SLE. Implementation of discussion if <80% of meds filled. Academic docs - 20/24 used + reinforcement, validated in 17 Pts, 11/24 asked open ended ?s. Pts thought it was right timing. ?does it change behaviour- ? Abst0063 @RheumNow #ACR22 https://t.co/UQbRgw5Emj
Janet Pope Janetbirdope ( View Tweet)
Sunday: ACR 2022 Daily Recap https://t.co/9naWAYwJIV
Dr. John Cush RheumNow ( View Tweet)
#ClinicalPearl woman with non-radiographic axSpA have LESS inactive disease vs MEN but NOT true if radiographic axSpA. 5 yr global study N=2633, independent of TNFi use - not sure why there are differences. Misclassification dx- unlikely. abst#1614 #ACR22 #ACRBest @RheumNowNews https://t.co/coNjwHOkLP
Janet Pope Janetbirdope ( View Tweet)
Lifetime career achievement āļø - first author of a paper in ACR year in review #ACR22 https://t.co/M5GrOcWY5X
Richard Conway RichardPAConway ( View Tweet)
$26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered (could only be obtained if ANA +); intervention aimed at inappropriate testing by ortho, IM, family med and neuro abst#0058 #ACR22 @rheumnow https://t.co/GoDHat6N3v
TheDaoIndex KDAO2011 ( View Tweet)
Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, swollen and tender joint counts week 48. Strange, the lowest dose (3mg bd) seems best. @RheumNow #ACR22 Abstr#1117 #ACRbest https://t.co/o4902tvZs8 https://t.co/t8oeMRGUS7
Richard Conway RichardPAConway ( View Tweet)
@RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at #ACR22
@jhrheumatology @JHRheumFellows
https://t.co/aSRHiJoIkE
Eric Dein ericdeinmd ( View Tweet)
Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR 2.53, >=5 comorbidities HR 3.19. Also higher for non-white, HR 4.02, and decreased with age. @RheumNow #ACR22 Abstr#1506 https://t.co/OFobRzhQVL https://t.co/IP08XlD66H
Richard Conway RichardPAConway ( View Tweet)
2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 years, but after trial termination, protective effects dissipated and were no longer significant. #ACR22 @RheumNow https://t.co/sLwoxeCR3y https://t.co/47wpWXF1W7
Dr. Rachel Tate uptoTate ( View Tweet)
HCQ does not prevent RA in CCP+ pts w/out clinical arthritis!
Stop RA: RCT HCQ vs. PBO in pts at-risk
Interim analysis 140+ pts
RA development HCQ 34% vs. PBO 36%
Trial interrupted as met futility criteria.
https://t.co/n31OmsjLhM
Abs#1604 #ACR22 @RheumNow #ACRBest https://t.co/NVYS8kB5to
Aurelie Najm AurelieRheumo ( View Tweet)
2022 ACR G/L for Integrative RA Intervent #ACR22
1 strong rec: consistent exercisee
27 conditional recs:
Rehab, Mediterr diet, against other diets, self-mgmt/CBT/acupunct
Conditional against electrotherapy, chiropractor
No rec for diet supplem
BMI, š¬: no RA spec recomm
@RheumNow https://t.co/cVFr6beQuJ
Eric Dein ericdeinmd ( View Tweet)
Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for dialysis 75.6% vs 16.7%, p=0.023. No effect on overall survival. 5-year mortality 70%, 1 year mortality 58%. @RheumNow #ACR22 Abstr#1530 https://t.co/cdYhEtqcHT https://t.co/lDWJto1cF0
Richard Conway RichardPAConway ( View Tweet)
Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in outcomes than late initiators (at least in MDA) in CorEvitas. @RheumNow #ACR22 Abstr#1493 https://t.co/oadxbG8TKS https://t.co/245xVTcKx1
Richard Conway RichardPAConway ( View Tweet)